In Brief: Perclose
This article was originally published in The Gray Sheet
Perclose: Completes human testing of its two-suture Prostar Plus 8F percutaneous vascular surgical system, a second-generation device for vascular closure of the arterial access sites created by catheterization procedures. Clinically evaluated in Canada and France, Prostar Plus incorporates technology from Perclose's Techstar one-suture device into a two-suture system. Perclose, which says it is "very pleased by the initial clinical experience with the Prostar Plus 8F," plans to launch the product this quarter in Europe, Japan and Canada, noting that a 10F product is under development...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.